Horizon Therapeutics says Amgen deal could close earlier than planned if FTC fails to block it

Horizon Therapeutics expects its $27.8 billion sale to Amgen to close as early as the end of the third quarter of this year, earlier than previously planned, if the Federal Trade Commission’s attempt to block the deal fails.